Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota for transplant
- Development stage
- Unknown
- Lead developer
- Tel Aviv Sourasky Medical Center
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota transplantation (FMT) is an investigational live microbial therapy being studied by Tel-Aviv Sourasky Medical Center for the treatment of moderate-to-severe atopic dermatitis in adults. The therapy involves transplanting fecal material from healthy donors into patients to restore the balance of the gut microbiota. In clinical trials, it is administered in capsule form. The proposed mechanism of action involves modulating the immune system through the gut-skin axis, rebalancing the Th1/Th2 immune response, reducing inflammatory markers like TNF-α and IgE, and improving intestinal barrier function. Clinical studies have shown that FMT can lead to significant improvements in disease severity scores (SCORAD and EASI) and reduce the need for topical corticosteroids. This therapy is currently in Phase 3 clinical trials for atopic dermatitis.
- Other names
- fecal transplantation-Tel-Aviv Sourasky Medical Center-atopic dermatitisfecal microbial transplantationFMT
Beyond the preview
Go deeper on fecal microbiota for transplant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota for transplant.